Novartis to acquire rights to remestemcel-L for Covid-19-related ARDS
Novartis will make upfront cash payment of $50m and equity/share subscription, plus performance-based milestones and royalties
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Nov 20
Novartis will make upfront cash payment of $50m and equity/share subscription, plus performance-based milestones and royalties
20 Nov 20
Baricitinib plus remdesivir is indicated for Covid-19 patients who require supplemental oxygen, invasive mechanical ventilation, or ECMO
19 Nov 20
The primary efficacy analysis in 170 confirmed cases of Covid-19 showed that BNT162b2 is 95% effective in preventing…
19 Nov 20
The EC authorisation is based on clinical data from two Phase 3 trials in a total of more…
18 Nov 20
The FDA breakthrough therapy designation is based on results from a randomised, multicentre, double-blind Phase 2b/3 study HPTN…
17 Nov 20
Moderna intends to seek the US FDA’s Emergency Use Authorisation (EUA) based on the interim data analysis of…
17 Nov 20
Lead and Roche will work together in research activities pertaining selection of a pre-clinical candidate for immune mediated…
16 Nov 20
Xofluza is an advanced antiviral, designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication
12 Nov 20
Pfizer and BioNTech are expected to begin the delivery of BNT162b2 vaccine by the end of 2020, pursuant…
12 Nov 20
The efficacy of the Sputnik V vaccine is calculated based on 20 confirmed Covid-19 cases, who received either…